The advancements in the Alopecia Areata treatment along with the emerging therapies by the leading pharma players are anticipated to fuel the market size during the forecast period (2021-30)

Alopecia Areata Market

DelveInsight’s Alopecia Areata market report offers comprehensive coverage of the current treatment practices, emerging drugs, Alopecia Areata market share of the individual therapies, current and forecasted Alopecia Areata market size from 2018 to 2030 segmented into 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan).

Some of the Key Highlights from the Alopecia Areata Market Report

• The National Alopecia Areata Foundation estimates that approximately 147 million people worldwide have or will develop Alopecia areata at some point in their lives.

• According to the National Organization of Rare Diseases, Alopecia Areata is most common in children, and approximately 2.5 million people in the United States are suffering from it.

• Companies across the globe such as Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly and Company, Incyte Corporation, Alcaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, and others are working toward the development of new treatment therapies for Alopecia Areata

• Key Alopecia Areata pipeline therapies such as PF-06651600, Jaktinib, Baricitinib, ATI-502, LH-8, CTP-543, and several others are expected to launch in the upcoming years and join the Alopecia Areata market soon.

• Pfizer’s PF-06651600 is an oral Janus kinase 3 (JAK3) inhibitor that is currently in phase III development for Alopecia Areata treatment. The US Food and Drug Administration designated PF-06651600 as a Breakthrough Therapy for the treatment of Alopecia Areata patients.

• Concert Pharmaceuticals is developing CTP-543, a novel oral Janus kinase (JAK) inhibitor. The US Food and Drug Administration (FDA) has granted CTP-543 Fast Track designation for the treatment of moderate-to-severe Alopecia Areata.

• Suzhou Zelgen Biopharmaceuticals is developing Jaktinib, an oral JAK 1, JAK 2, and JAK 3 inhibitor, for the treatment of Severe Alopecia Areata.

For further information on alopecia areata, request for sample @ Alopecia Areata Market Outlook

The Alopecia Areata market report also discusses current Alopecia Areata treatment practices/algorithms, market drivers, market barriers, and unmet medical needs in order to curate the best opportunities and assess the market’s underlying potential.

Alopecia Areata: Overview

Alopecia Areata (AA) is a common autoimmune skin disease that causes hair loss on the scalp, face, and occasionally on other parts of the body. The affected hair follicles are attacked by a person’s immune system (white blood cells), resulting in the hair growth stage being stalled. Hair follicles remain alive in Alopecia Areata, and hair can regrow at any time. Alopecia Areata typically begins with one or more patches of hair loss on the scalp that may be small, round, or smooth, and can progress to total scalp hair loss or total body hair loss.

Alopecia Areata Epidemiology Segmentation

The Alopecia Areata report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Alopecia Areata Prevalent Cases 

• Alopecia Areata Subtype-Specific Prevalent Cases 

• Alopecia Areata Age-Specific Prevalent Cases

• Alopecia Areata Diagnosed and Treatable Cases 

Alopecia Areata Treatment Landscape

There is currently no cure and no FDA-approved drugs for Alopecia Areata. So, therefore, the current Alopecia Areata treatment includes: 

• Local Corticosteroids

• Systemic Corticosteroids

• Laser Treatment

• Contact immunotherapy

Alopecia Areata Market

The dynamics of the Alopecia Areata market size are expected to change in the coming years as a result of advancements in diagnosis methodologies, increased disease awareness, and increased healthcare spending globally, as well as the launch of emerging therapies such as Jaktinib, Baricitinib, ATI-502, and others during the forecast period of 2021–2030.

Learn more about the alopecia areata drugs in development @ Alopecia Areata Treatment Market

Alopecia Areata Pipeline Therapies and Key Companies 

• PF-06651600: Pfizer 

• Jaktinib: Suzhou Zelgen Biopharmaceuticals

• Baricitinib: Eli Lilly and Company/Incyte Corporation

• ATI-502: Alcaris Therapeutics 

• LH-8: Legacy Healthcare 

• CTP-543: Concert Pharmaceuticals

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Alopecia Market

Get a comprehensive analysis of Alopecia pipeline therapies and key companies such as Follicum AB, Concert Pharmaceuticals Inc., Daiichi Sankyo, Johnson & Johnson, Merck & Co., Inc., Aclaris Therapeutics, Inc., Fagron, Sun Pharmaceutical Industries Ltd., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/